Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Corporate Update (August 2021)
14 slides from Sorrento Therapeutics's corporate update, Aug 9, 2021
Slide 1: SARS-CoV-2 Vaccine Countermeasures
SARS - CoV - 2 Vaccine Countermeasures August 20 21 NASDAQ : SRNE © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 1 Exhibit 99.1
Slide 2: 2 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved
2 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved
Slide 3: Sorrento company overview at a glance
HQ in San Diego, CA ~ 700 Employees worldwide ~100 Employees with PhDs & MDs >5 00,000 SF Research and cGMP Manufacturing Facilities 1 FDA Approved Drug ZTlido ® (lidocaine topical system)1.8% NASDAQ: SRNE 7 cGMP Manufacturing Sites (5 USA, 2 China) mAbs, Small Molecule, ADC, Plasmid DNA, Lymphatic
Slide 4: Targeting the emerging pandemic strains of SARS-CoV-2
TARGETING THE EMERGING PANDEMIC STRAINS OF SARS - CoV - 2 4 As new pandemic strains emerge, Sorrento is developing vaccine solutions in response to these changes. • Thermostable Nucleic Acid - based Platforms • Needle - Free Lymphatic Delivery of mRNA - Encoded Spike Antigens Virus mutations identif
Slide 5: STI mRNA Vaccine: mRNAs Encode Variant Spike Proteins
STI mRNA Vaccine: mRNAs Encode SARS - CoV - 2 Variant Spike Proteins Dead Dead Daniel Wrapp et al. Science 2020;367:1260 - 1263 Spike protein: • the main target for neutralizing antibodies • binds to hACE2 to initiate infection Spike Protein SARS - CoV - 2 Variant of Concern Spike Proteins Spike 3’
Slide 6: Sorrento COVID-mRNA Vaccine Candidate Target Product Profile
Sorrento COVID - 19 mRNA Vaccine Candidate Target Product Profile Room temperature Storage condition Immunogen Sorrento Washington Alpha Gamma Delta Administration Needle - free Lymphatic Drug Delivery (LDD) ( Sofusa ® MuVaxx Ρ ) © 2021 Sorrento Therapeutics, Inc. All Rights Reserved Intramuscular i
Slide 7: Sorrento Multivalent mRNA Vaccine Production and Administration
© 2021 Sorrento Therapeutics, Inc. All Rights Reserved Spike 3’ UTR 5’ UTR — AAAAAAAA C A P mRNA Spike 3’ UTR 5’ UTR — AAAAAAAA C A P Spike 3’ UTR 5’ UTR — AAAAAAAA C A P Spike 3’ UTR 5’ UTR — AAAAAAAA C A P Spike 3’ UTR 5’ UTR — AAAAAAAA C A P DNA Washington Alpha Beta Gamma Delta IVT LNP formulati
Slide 8: Mode of Action of mRNA Coronavirus Vaccine
Mode of Action of mRNA Coronavirus Vaccine Dead Dead Spike 3’ UTR 5’ UTR — AAAAAAAA CAP CD4 T cell CD8 T cell B cell Antigen Presenting Cell Neutralizing Antibodies Cell Mediated Immunity LNP mRNA Formulation Enters Cell © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 8
Slide 9: Designer mRNA: Spike Protein Cleavage Site Mutation Increases Surface Expression
Designer mRNA: Spike Protein Cleavage Site Mutation Increases the Surface Expression of mRNAs © 2021 Sorrento Therapeutics, Inc. All Rights Reserved Washington Alpha Beta Gamma Spike protein antibody Delta RBD S1/S2 cleavage site Mutation S1 S2 Wild - type mRNA Designer Mutant mRNA Cleavage Site mut
Slide 10: Needle-Free Lymphatic Drug Delivery Generates Anti-Spike Immune Responses at 1 µg Dose
Needle - Free Lymphatic Drug Delivery (LDD) ( Sofusa ® MuVaxx Ρ ) Generates Anti - SARS - CoV - 2 Immune Responses at a 1 m g Dose Similar to Those Achieved Following Intramuscular Injection (IM) of 10 m g *Needle - Free Lymphatic Drug Delivery (LDD) ( Sofusa ® MuVaxx Ρ ) © 2021 Sorrento Therapeutic
Slide 11: In Vivo Comparability Study for Lyophilized Spike-mRNA-LNP
* STI LNP and STI LNP Lyophilized are different formulations, Same mRNA, different compositions © 2021 Sorrento Therapeutics, Inc. All Rights Reserved In Vivo Comparabililty Study for Lyophilized Spike - mRNA - LNP (IM 1 m g) Day 7 Day 14 10 2 10 3 10 4 10 5 A n t i - S 1 I g G ( n g / m L ) STI LNP
Slide 12: Sorrento Needle-Free Delivery Technology Designed to Maximize Immunization Efficiency
Sorrento Needle - Free Delivery Technology Designed to Maximize Immunization Efficiency Lymphatic vessels Brachial LN (1) Iwasaki et al., “Adaptive Immunity”, BioRender.com, 2020 Lymph nodes are the primary organs for generating adaptive immune responses as dendritic cells activate T and B cells. Th
Slide 13: Sorrento cGMP mRNA Manufacturing for Clinical Trials and Commercialization
Sorrento cGMP mRNA Manufacturing for Clinical Trials and Commercialization • 7 cGMP Manufacturing Sites (5 USA, 2 China) • Unique process utilizing automation to ensure consistent repeatability, quality control and on - demand manufacturing © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 13
Slide 14: Sorrento mRNA Vaccine Solutions
Sorrento mRNA Vaccine Solutions • Sofusa ® MuVaxx Ρ platform is designed to improve immune responses following COVID vaccines vs. subcutaneous and intradermal injections. • Established micro - fabrication and large - scale DNA and mRNA GMP manufacturing in place to supply COVID - 19 vaccine campaign
Sorrento Therapeutics — Corporate Update (August 2021) on 6ix